Histopathologic and immunohistochemical features of tissue adherent to multitined electrodes after RF ablation of liver malignancies can help predict local tumor progression: Initial results 1

Radiology

Volumn 249, Issue 1, 2008, Pages 364-374

  Sofocleous, Constantinos T ^a   Nascimento, Rodrigo G ^a   Petrovic, Lydia M ^b   Klimstra, David S ^a   Gonen, Mithat ^a   Brown, Karen T ^a   Brody, Lynn A ^a   Covey, Anne M ^a   Thornton, Raymond H ^a   Fong, Yuman ^a   Solomon, Stephen B ^a   Schwartz, Lawrence H ^a   Dematteo, Ronald P ^a   Getrajdman, George I ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CEFAZOLIN; KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; DATA BASE; ELECTRODE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MICROPHOTOGRAPHY; PREDICTION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RISK FACTOR; TUMOR VOLUME; APOPTOSIS; CATHETER ABLATION; CELL DIVISION; DISEASE COURSE; INSTRUMENTATION; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; APOPTOSIS; CATHETER ABLATION; CELL DIVISION; DISEASE PROGRESSION; ELECTRODES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 53749085743     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2491071752     Document Type: Article

References (53)

1. Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 2006;141:181-190.
2. Motola-Kuba D, Zamora-Valdes D, Uribe M, Mendez-Sanchez N. Hepatocellular carcinoma: an overview. Ann Hepatol 2006;5:16-24.
3. Hanna NN. Radiofrequency ablation of primary and metastatic hepatic malignancies. Clin Colorectal Cancer 2004;4:92-100.
4. Hildebrand P, Kleemann M, Roblick UJ, et al. Radiofrequency-ablation of unresectable primary and secondary liver tumors: results in 88 patients. Langenbecks Arch Surg 2006;391:118-123.
5. Gillams AR. The use of radiofrequency in cancer. Br J Cancer 2005;92:1825-1829.
6. Curley SA, Izzo F. Radiofrequency ablation of primary and metastic liver tumors. Surg Technol Int 2002;10:99-106.
7. Chen MH, Yang W, Yan K, et al. Treatment efficacy of radiofrequency ablation of 338 patients with hepatic malignant tumor and the relevant complications. World J Gastroenterol 2005;11:6395- 6401.
8. Sofocleous CT, Nascimento RG, Gonen M, et al. Radiofrequency ablation in the management of liver metastases from breast cancer. AJR Am J Roentgenol 2007;189: 883-889.
9. Ng KK, Poon RT. Radiofrequency ablation for malignant liver tumor. Surg Oncol 2005;14:41-52.
10. Rossi S, Garbagnati F, Lencioni R, et al. Percutaneous radio-frequency thermal ablation of nonresectable hepatocellular carcinoma after occlusion of tumor blood supply. Radiology 2000;217:119-126.
11. Harrison LE, Koneru B, Bahramipour P, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg 2003;197:759-764.
12. Solbiati L, Livraghi T, Goldberg SN, et al. Percutaneous radiofrequency ablation of hepatic metastases from colorectal cancer: long-term results in 117 patients. Radiology 2001;221:159-166.
13. White RR, Avital I, Sofocleous CT, et al. Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg 2007;11:256-263.
14. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio- frequency ablation: complications encountered in a multicenter study. Radiology 2003;226:441-451.
15. Lencioni R, Crocetti L, Cioni D, Della Pina C, Bartolozzi C. Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises. Invest Radiol 2004;39:689- 697.
16. White TJ, Roy-Choudhury SH, Breen DJ, et al. Percutaneous radiofrequency ablation of colorectal hepatic metastases: initial experience-an adjunct technique to systemic chemotherapy for those with inoperable colorectal hepatic metastases. Dig Surg 2004;21:314-320.
17. Siperstein A, Garland A, Engle K, et al. Laparoscopic radiofrequency ablation of primary and metastatic liver tumors: technical considerations. Surg Endosc 2000;14:400-405.
18. Adam R, Hagopian EJ, Linhares M, et al. A comparison of percutaneous cryosurgery and percutaneous radiofrequency for unresectable hepatic malignancies. Arch Surg 2002;137:1332-1339.
19. Sofocleous CT, Klein K, Hubbi B, et al. Histopathologic evaluation of tissue extracted on the radiofrequency probe after ablation of liver tumors: preliminary findings. AJR Am J Roentgenol 2004;183:209-213.
20. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol 1999;15:269-290.
21. Yang J, Ramnath N, Moysich KB, et al. Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer 2006;6:203.
22. Choi H, Loyer EM, DuBrow RA, et al. Radio- frequency ablation of liver tumors: assessment of therapeutic response and complications. RadioGraphics 2001;21(Spec Issue):S41-S54.
23. Goldberg SN, Grassi CJ, Cardella JF, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria. Radiology 2005;235:728-739.
24. Davison AC, Hinkley DV. Bootstrap methods and their application. Cambridge, England: Cambridge University Press, 1997.
25. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989;84:1065-1073.
26. Graur F, Vlad L, Furcea L, Miclaus D, Osian G. Radiofrequency ablation of liver tumors: technique and preliminary results [in Romanian]. Chirurgia (Bucur) 2006;101:159-167.
27. Curley SA. Radiofrequency ablation ofmalig- nant liver tumors. Ann Surg Oncol 2003;10: 338-347.
28. Rossi S, Buscarini E, Garbagnati F, et al. Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode. AJR Am J Roentgenol 1998;170:1015-1022.
29. Solbiati L, Goldberg SN, Ierace T, et al. Hepatic metastases: percutaneous radio-frequency ablation with cooled-tip electrodes. Radiology 1997;205:367-373.
30. Pulvirenti A, Garbagnati F, Regalia E, et al. Experience with radiofrequency ablation of small hepatocellular carcinomas before liver transplantation. Transplant Proc 2001;33: 1516-1517.
31. Goldberg SN, Gazelle GS, Compton CC, Mueller PR, Tanabe KK. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 2000;88:2452-2463.
32. Morimoto M, Sugimori K, Shirato K, et al. Treatment of hepatocellular carcinoma with radiofrequency ablation: radiologic-histologic correlation during follow-up periods. Hepatology 2002;35:1467-1475.
33. Hansen PD, Rogers S, Corless CL, Swanstrom LL, Siperstien AE. Radiofrequency ablation lesions in a pig liver model. J Surg Res 1999;87:114-121.
34. Rossi S, Fornari F, Pathies C, Buscarini L. Thermal lesions induced by 480 KHz localized current field in guinea pig and pig liver. Tumori 1990;76:54-57.
35. Leonardi E, Girlando S, Serio G, et al. PCNA and Ki-67 expression in breast carcinoma: correlation with clinical and biological variables. J Clin Pathol1992;45:416-419.
36. Nolte M, Werner M, Nasarek A, et al. Expression of proliferation associated antigens and detection of numerical chromosome aberrations in primary human liver tumours: relevance to tumour characteristics and prognosis. J Clin Pathol1998;51:47-51.
37. Ben-Izhak O, Bar-Chana M, Sussman L, et al. Ki-67 antigen and PCNA proliferation markers predict survival in anorectal malignant melanoma. Histopathology 2002;41:519-525.
38. Urruticoechea A, Smith IE, Dowsett M. Proliferation marker ki-67 in early breast cancer. J Clin Oncol2005;23:7212-7220.
39. Tollefson MK, Thompson RH, Sheinin Y, et al. Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal carcinoma and not surrogates for each other. Cancer 2007;110:783-790.
40. King KL, Hwang JJ, Chau GY, et al. Ki-67 expression as a prognostic marker in patients with hepatocellular carcinoma. J Gastroenterol Hepatol1998;13:273-279.
41. Fernandez-Cebrian JM, Nevado Santos M, Vorwald Kuborn P, et al. Can the clinical outcome in stage II colon carcinomas be predicted by determination ofmolecular marker expression? Clin Transl Oncol 2007;9:663-670.
42. Garrity MM, Burgart LJ, Mahoney MR, et al. Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study. J Clin Oncol 2004;22:1572-1582.
43. Toquet C, Le Neel JC, Guillou L, et al. Elevated (≤10%) MIB-1 proliferative index correlates with poor outcome in gastric stromal tumor patients: a study of 35 cases. Dig Dis Sci 2002;47:2247-2253.
44. Vilar E, Salazar R, Perez-Garcia J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer 2007;14:221-232.
45. Weber JC, Nakano H, Bachellier P, et al. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg 2001;182:81-88.
46. Scalzo DA, Kallakury BV, Gaddipati RV, et al. Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas. Am J Clin Pathol 1998;109:163-168.
47. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-322.
48. Fong Y, Fortner J, Sun R. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230:309-318.
49. Yu HC, Cheng JS, Lai KH, et al. Factors for early tumor recurrence of single small hepatocellular carcinoma after percutaneous radiofrequency ablation therapy. World J Gastroenterol 2005;11:1439-1444.
50. Hori T, Nagata K, Hasuike S, et al. Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. J Gastroenterol 2003;38:977-981.
51. Zhang YJ, Liang HH, Chen MS, et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology 2007;244:599-607.
52. Berber E, Pelley R, Siperstein AE. Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 2005;23:1358-1364.
53. Abitabile P, Hartl U, Lange J, Maurer CA. Radiofrequency ablation permits an effective treatment for colorectal liver metastasis. Eur J Surg Oncol 2007;33:67-71.